Clinical Trial Update: Effects of Cilostazol on VEGF and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating cilostazol's effect on VEGF and oxidative stress biomarkers in hemodialysis patients with peripheral vascular disease. The study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Peripheral Vascular Disease

Drugs mentioned

• Cilostazol (Cilostazol)

Snippet

Sponsor: Tungs' Taichung Metroharbour Hospital | Conditions: Hemodialysis Patients, Peripheral Vascular Disease | Phase 4 | Status: COMPLETED